What type of study is this?

This is a Quantitative Study study.

September 16, 2025Neurology Clinical Practice

Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis

View Full Paper

Ask AI

Bookmark

Out-of-pocket costs for brand-name DMTs decreased by 68%-77% after the IRA implementation in 2025.
Annual OOP costs for generic DMTs dropped significantly, ranging from $212 to $2,000 post-IRA.
Enrolling in the Medicare Prescription Payment Plan can reduce monthly OOP costs to as low as $167.
Purchasing generic DMTs via direct-to-consumer pharmacies may offer even lower costs for beneficiaries.

Authors

PLPengxiang LiHenan Provincial People's Hospital JLJohn K. LinThe University of Texas MD Anderson Cancer Center MKMatthew J. KlebanoffBeth Israel Deaconess Medical Center

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Analysis reveals significant reduction in out-of-pocket costs for disease-modifying therapies under Medicare reforms, highlighting potential savings and payment plans.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68d4566c31b076d99fa5b9b0 https://doi.org/10.1212/cpj.0000000000200536

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals significant reduction in out-of-pocket costs for disease-modifying therapies under Medicare reforms, highlighting potential savings and payment plans.

Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis

Key Points

Discussion

Implication

Cite This Study

Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider